BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...would assist with manufacturing and testing of the vaccine. The CDMO acquired gene therapy manufacturer Paragon Bioservices Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Keith Katkin, who will remain as a board adviser. Robinson was president and COO of Paragon Bioservices Inc....
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...is nearly 16x MaSTherCell’s 2018 revenue of €17.4 million ($19.9 million). Catalent paid 6x for Paragon Bioservices Inc....
...to $61.65 on Monday. The deal is expected to close this quarter. Stephen Hansen, Associate Editor MaSTherCell S.A. Paragon Bioservices Inc. Catalent...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Pharma N.V. (Euronext:KDS) CytoSen Therapeutics Inc. 04/17/19 NA $13.3 $51 (B) $64.3 Catalent Inc. (NASDAQ:CTLT) Paragon Bioservices Inc....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...development and manufacturing company Brammer Bio for $1.7 billion. Then in April, Catalent Inc. acquired Paragon Bioservices Inc....
BioCentury | Apr 15, 2019
Company News

$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing

...The 6x multiple Catalent is paying for gene therapy manufacturer Paragon Bioservices suggests buyers believe gene therapy...
...approved in the next few years. Catalent Inc. (NASDAQ:CTLT) will pay $1.2 billion to acquire Paragon Bioservices Inc....
...to close this quarter. On Monday, Catalent gained $5.15 (13%) to $44.41. Mark Zipkin, Staff Writer Catalent Inc. Paragon Bioservices Inc. gene...
BioCentury | Mar 17, 2014
Company News

Cevec, Paragon Bioservices Inc. deal

...reached for next steps (see BioCentury, Aug. 13, 2012). Cevec Pharmaceuticals GmbH , Cologne, Germany Paragon Bioservices Inc....
BioCentury | Aug 13, 2012
Company News

Cevec, Paragon Bioservices deal

...to produce glycosylated human proteins. Details were not disclosed. Cevec Pharmaceuticals GmbH , Cologne, Germany Paragon Bioservices Inc....
BioCentury | Jan 23, 2012
Company News

Paragon Bioservices Inc. infectious news

...support the efficacy and potency of filovirus vaccine candidates against the Ebola and Marburg viruses. Paragon Bioservices Inc....
Items per page:
1 - 9 of 9
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...would assist with manufacturing and testing of the vaccine. The CDMO acquired gene therapy manufacturer Paragon Bioservices Inc....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Keith Katkin, who will remain as a board adviser. Robinson was president and COO of Paragon Bioservices Inc....
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...is nearly 16x MaSTherCell’s 2018 revenue of €17.4 million ($19.9 million). Catalent paid 6x for Paragon Bioservices Inc....
...to $61.65 on Monday. The deal is expected to close this quarter. Stephen Hansen, Associate Editor MaSTherCell S.A. Paragon Bioservices Inc. Catalent...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Pharma N.V. (Euronext:KDS) CytoSen Therapeutics Inc. 04/17/19 NA $13.3 $51 (B) $64.3 Catalent Inc. (NASDAQ:CTLT) Paragon Bioservices Inc....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...development and manufacturing company Brammer Bio for $1.7 billion. Then in April, Catalent Inc. acquired Paragon Bioservices Inc....
BioCentury | Apr 15, 2019
Company News

$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing

...The 6x multiple Catalent is paying for gene therapy manufacturer Paragon Bioservices suggests buyers believe gene therapy...
...approved in the next few years. Catalent Inc. (NASDAQ:CTLT) will pay $1.2 billion to acquire Paragon Bioservices Inc....
...to close this quarter. On Monday, Catalent gained $5.15 (13%) to $44.41. Mark Zipkin, Staff Writer Catalent Inc. Paragon Bioservices Inc. gene...
BioCentury | Mar 17, 2014
Company News

Cevec, Paragon Bioservices Inc. deal

...reached for next steps (see BioCentury, Aug. 13, 2012). Cevec Pharmaceuticals GmbH , Cologne, Germany Paragon Bioservices Inc....
BioCentury | Aug 13, 2012
Company News

Cevec, Paragon Bioservices deal

...to produce glycosylated human proteins. Details were not disclosed. Cevec Pharmaceuticals GmbH , Cologne, Germany Paragon Bioservices Inc....
BioCentury | Jan 23, 2012
Company News

Paragon Bioservices Inc. infectious news

...support the efficacy and potency of filovirus vaccine candidates against the Ebola and Marburg viruses. Paragon Bioservices Inc....
Items per page:
1 - 9 of 9